Naturally occurring oncolytic viruses are live, replicationproficient
viruses that specifically infect human cancer cells
while sparing normal cell counterparts. Since the eradication
of smallpox in the 1970s with the aid of vaccinia viruses,
the vaccinia viruses and other genera of poxviruses have
shown various degrees of safety and efficacy in pre-clinical
or clinical application for human anti-cancer therapeutics.
Furthermore, we have recently discovered that cellular tumor
suppressor genes are important in determining poxviral
oncolytic tropism. Since carcinogenesis is a multi-step
process involving accumulation of both oncogene and tumor
suppressor gene abnormalities, it is interesting that poxvirus
can exploit abnormal cellular tumor suppressor signaling
for its oncolytic specificity and efficacy. Many tumor suppressor
genes such as p53, ATM, and RB are known to play
important roles in genomic fidelity/maintenance. Thus, tumor
suppressor gene abnormality could affect host genomic
integrity and likely disrupt intact antiviral networks due to
accumulation of genetic defects, which would in turn result
in oncolytic virus susceptibility. This review outlines the characteristics
of oncolytic poxvirus strains, including vaccinia,
myxoma, and squirrelpox virus, recent progress in elucidating
the molecular connection between oncogene/tumor
suppressor gene abnormalities and poxviral oncolytic tropism,
and the associated preclinical/clinical implications. I would
also like to propose future directions in the utility of poxviruses
for oncolytic virotherapy.
Citations
Citations to this article as recorded by
Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy Shashi Gujar, Jonathan G. Pol, Vishnupriyan Kumar, Manuela Lizarralde-Guerrero, Prathyusha Konda, Guido Kroemer, John C. Bell Nature Protocols.2024; 19(9): 2540. CrossRef
A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells Yanrong Zhou, Qianpeng Wang, Qi Ying, Xiaomei Zhang, Ting Ye, Kan Chen, Gongchu Li Marine Drugs.2023; 21(2): 77. CrossRef
Poxvirus-driven human diseases and emerging therapeutics Kritika Srinivasan Rajsri, Mana Rao Therapeutic Advances in Infectious Disease.2022;[Epub] CrossRef
The O H system: A panorama view of the PPV-host interaction Yongzhong Yu, Zhengxing Lian, Yudong Cui Infection, Genetics and Evolution.2022; 98: 105220. CrossRef
Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice Hajime Kurosaki, Motomu Nakatake, Teruhisa Sakamoto, Nozomi Kuwano, Masato Yamane, Kenta Ishii, Yoshiyuki Fujiwara, Takafumi Nakamura Cells.2021; 10(5): 985. CrossRef
Oncolytic Vaccinia Virus Expressing White-Spotted Charr Lectin Regulates Antiviral Response in Tumor Cells and Inhibits Tumor Growth In Vitro and In Vivo Xue Wang, Ningning Zhou, Tingting Liu, Xiaoyuan Jia, Ting Ye, Kan Chen, Gongchu Li Marine Drugs.2021; 19(6): 292. CrossRef
Novel Oncolytic Virus Armed with Cancer Suicide Gene and Normal Vasculogenic Gene for Improved Anti-Tumor Activity Su-Nam Jeong, So Young Yoo Cancers.2020; 12(5): 1070. CrossRef
Oncolytic Virotherapy for Malignant Tumor: Current Clinical Status Yuhui Zhang, Zhuoming Liu Current Pharmaceutical Design.2020; 25(40): 4251. CrossRef
Viral and metazoan poxins are cGAMP-specific nucleases that restrict cGAS–STING signalling James B. Eaglesham, Youdong Pan, Thomas S. Kupper, Philip J. Kranzusch Nature.2019; 566(7743): 259. CrossRef
Targeted therapy of human glioblastoma combining the oncolytic properties of parvovirus H-1 and attenuated strains of the vaccinia virus A. V. Tkacheva, G. F. Sivolobova, A. A. Grazhdantseva, O. B. Shevelev, I. A. Razumov, E. L. Zavjalov, V. B. Loktev, G. V. Kochneva Molecular Genetics Microbiology and Virology (Russian version).2019; 37(2): 83. CrossRef
Poxvirus oncolytic virotherapy Lino E. Torres-Domínguez, Grant McFadden Expert Opinion on Biological Therapy.2019; 19(6): 561. CrossRef
Targeted Therapy of Human Glioblastoma Combining the Oncolytic Properties of Parvovirus H-1 and Attenuated Strains of the Vaccinia Virus A. V. Tkacheva, G. F. Sivolobova, A. A. Grazhdantseva, O. B. Shevelev, I. A. Razumov, E. L. Zavjalov, V. B. Loktev, G. V. Kochneva Molecular Genetics, Microbiology and Virology.2019; 34(2): 140. CrossRef
Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines Edmund K. Moon, Liang-Chuan S. Wang, Kheng Bekdache, Rachel C. Lynn, Albert Lo, Stephen H. Thorne, Steven M. Albelda OncoImmunology.2018; 7(3): e1395997. CrossRef
Development of improved therapeutic mesothelin-based vaccines for pancreatic cancer Michael White, Andrew Freistaedter, Gwendolyn J. B. Jones, Emmanuel Zervos, Rachel L. Roper, Aamir Ahmad PLOS ONE.2018; 13(2): e0193131. CrossRef
Mutagenic repair of double-stranded DNA breaks in vaccinia virus genomes requires cellular DNA ligase IV activity in the cytosol Rutger David Luteijn, Ingo Drexler, Geoffrey L. Smith, Robert Jan Lebbink, Emmanuel J. H. J. Wiertz Journal of General Virology.2018; 99(6): 790. CrossRef
Oncolytic viruses: emerging options for the treatment of breast cancer Yogesh R. Suryawanshi, Tiantian Zhang, Karim Essani Medical Oncology.2017;[Epub] CrossRef
Primary lymphocyte infection models for KSHV and its putative tumorigenesis mechanisms in B cell lymphomas Sangmin Kang, Jinjong Myoung Journal of Microbiology.2017; 55(5): 319. CrossRef
Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro Elena P. Goncharova, Julia S. Ruzhenkova, Ivan S. Petrov, Sergey N. Shchelkunov, Marina A. Zenkova Journal of Translational Medicine.2016;[Epub] CrossRef
Oncolytic virotherapy for urological cancers Zahid Delwar, Kaixin Zhang, Paul S. Rennie, William Jia Nature Reviews Urology.2016; 13(6): 334. CrossRef
Features of the Antitumor Effect of Vaccinia Virus Lister Strain Evgeniy Zonov, Galina Kochneva, Anastasiya Yunusova, Antonina Grazhdantseva, Vladimir Richter, Elena Ryabchikova Viruses.2016; 8(1): 20. CrossRef
Single-particle characterization of oncolytic vaccinia virus by flow virometry Vera A. Tang, Tyler M. Renner, Oliver Varette, Fabrice Le Boeuf, Jiahu Wang, Jean-Simon Diallo, John C. Bell, Marc-André Langlois Vaccine.2016; 34(42): 5082. CrossRef
Use of Reporter Genes in the Generation of Vaccinia Virus-Derived Vectors Sally Al Ali, Sara Baldanta, Mercedes Fernández-Escobar, Susana Guerra Viruses.2016; 8(5): 134. CrossRef
Naturally occurring reoviruses for human cancer therapy Manbok Kim BMB Reports.2015; 48(8): 454. CrossRef
Reoviral Oncotropism Against c-Myc Overexpressing HS 68 Cells Manbok Kim Journal of Bacteriology and Virology.2015; 45(2): 126. CrossRef